(R)-2-氨基-2-(4-溴苯基)乙醇盐酸盐 | 1916569-82-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-2-氨基-2-(4-溴苯基)乙醇盐酸盐
• 英文名称: (2R)-2-amino-2-(4-bromophenyl)ethanol hydrochloride
• 英文别名: (R)-2-Amino-2-(4-bromophenyl)ethanol hydrochloride；(2R)-2-amino-2-(4-bromophenyl)ethanol;hydrochloride
• CAS: 1916569-82-8
• 化学式: C₈H₁₀BrNO*ClH
• 分子量: 252.538
• InChiKey: PQQGURGSEYFRCS-QRPNPIFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.86
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-2-氨基-2-(4-溴苯基)乙醇盐酸盐 在 copper(l) iodide 、 碳酸氢钠 、 sodium L-prolinate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 二甲基亚砜 为溶剂， 反应 21.0h， 生成 tert-butyl (R)-(1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)carbamate
  参考文献：
  名称：

  DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA

  摘要：

  提供了化合物的新颖结构（I）：其药用盐，以及其药物组合物，可用于治疗由RORγ介导的疾病和紊乱。还提供了包含新颖结构（I）化合物的药物组合物，以及在治疗一种或多种炎症性、代谢性、自身免疫和其他疾病或紊乱中使用它们的方法。

  公开号：

  US20160122345A1

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• Dihydropyrrolopyridine inhibitors of ROR-gamma
  申请人：Vitae Pharmaceuticals, LLC

  公开号：US11001583B2

  公开（公告）日：2021-05-11

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  本文提供了新型的式 (I) 化合物： 其药学上可接受的盐及其药物组合物，可用于治疗由 RORγ 介导的疾病和失调。此外，还提供了包含式（I）新型化合物的药物组合物及其用于治疗一种或多种炎症、代谢、自身免疫和其他疾病或紊乱的方法。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas Operations, Inc.

  公开号：EP3658548A1

  公开（公告）日：2020-06-03
• US9663515B2
  申请人：——

  公开号：US9663515B2

  公开（公告）日：2017-05-30
• [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA DÉGRADATION CIBLÉE DU RÉCEPTEUR DES ANDROGÈNES
  申请人：ARVINAS INC

  公开号：WO2019023553A1

  公开（公告）日：2019-01-31

  The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.